![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Switching From Boosted Protease Inhibitor-based Regimens to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
for Treatment of HIV-1 Infection: Subgroups Analysis by Baseline Regimen
|
|
|
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Pierre-Marie Girard,1 Gregory D. Huhn,2,* Edwin DeJesus,3 Donghan Luo,4 Romana Petrovic,5 Kimberley Brown,5 Eric Y. Wong6
1University Pierre and Marie Curie, Paris, France; 2The Ruth M. Rothstein CORE Center, Chicago, IL, USA; 3Orlando Immunology Center, Orlando, FL, USA; 4Janssen Research & Development, LLC, Titusville, NJ, USA; 5Janssen Research & Development, Beerse, Belgium; 6Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
![0727181](../images%20/072718/072718-5/0727181.gif)
![0727182](../images%20/072718/072718-5/0727182.gif)
![0727183](../images%20/072718/072718-5/0727183.gif)
![0727184](../images%20/072718/072718-5/0727184.gif)
![0727185](../images%20/072718/072718-5/0727185.gif)
![0727186](../images%20/072718/072718-5/0727186.gif)
![0727187](../images%20/072718/072718-5/0727187.gif)
![0727188](../images%20/072718/072718-5/0727188.gif)
![0727189](../images%20/072718/072718-5/0727189.gif)
![07271810](../images%20/072718/072718-5/07271810.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|